Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05585034 · ClinicalTrials.gov registry record · Phase 1
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
A Phase 1 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT05585034 is a Phase 1 study that has completed, run by Xencor. The registered enrollment target is 60 participants.
The verdict
NCT05585034, a Phase 1 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.
Interventions
- BIOLOGICAL XmAb®808
- BIOLOGICAL Keytruda® (pembrolizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2025-05-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05585034
The ClinicalTrials.gov registry entry for NCT05585034 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XmAb®808 is the first listed.
NCT05585034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05585034 about?
NCT05585034 is a clinical study titled "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) an...
What is the current status of trial NCT05585034?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2022-12-14. Estimated completion is 2025-05-20.
What interventions are being tested in trial NCT05585034?
The interventions under investigation include: XmAb®808 (BIOLOGICAL), Keytruda® (pembrolizumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05585034?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.